Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Effect of the COVID-19 Pandemic on Kidney Transplant and on Chronic Dialysis Patients

Thamiris Quiqueto Marinelli Amseia,b,1, Fernanda Salomão Gorayeb-Polacchini,a,b,1, Heloisa Cristina Caldas9, Ida Maria Maximina Fernandes-Charpioa,b,9, Maria Alice Sperto Ferreira-Baptista,a,9, and Mario Abbud-Filho,a,b,*

aLaboratory of Immunology and Experimental Transplantation - LITEX, Medical School of Sao Jose do Rio Preto-FAMERP, Sao Jose do Rio Preto, Brazil; and bKidney Transplant and Dialysis Unit, Hospital de Base-FUNFARME, Sao Jose do Rio Preto, Brazil

ABSTRACT

Background. The reported fatality rates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients receiving maintenance dialysis or kidney transplant are higher than in the general population. The aim of this study was to evaluate the impact of SARS-CoV-2 infection in chronic dialysis patients (DPs) compared with kidney transplant recipients (KTxRs).

Methods. A study evaluating 266 COVID-19-positive patients (112 DPs and 154 KTxRs) was conducted in a single center from March 1, 2020, to June 30, 2021. All patients were confirmed for COVID-19 infection by reverse transcription polymerase chain reaction or antigen test.

Results. KTxRs were younger (49 ± 12.4 vs 61 ± 14.6 years; \( P < .0001 \)) and had significantly fewer coexisting disorders than the DPs. A higher percentage of KTxRs required hospitalization (70% vs 49.4%, \( P = .002 \)) and intensive care unit admission (39% vs 25%, \( P = .01 \)). The fatality rate was 24% in both groups.

Discussion. There is no consensus among studies about the higher fatality rate between KTxRs and DPs who develop COVID-19. In our study, we also did not find a different fatality rate.

Conclusion. In spite of KTxRs being younger and having fewer coexisting disorders, compared with DPs, they presented a higher hospitalization and intensive care unit necessity rate but a similar fatality rate.

COVID-19 was first reported in Wuhan, China, in December of 2019 and became a world health emergency [1]. In February 2020, the first case of COVID-19 was reported in Brazil, which then became one of the most affected countries. The country had more than 21 million confirmed cases and more than 600,000 deaths, corresponding to an overall case fatality rate of 2.8% [2]. Because of underlying chronic kidney disease associated with comorbid conditions, chronic dialysis patients (DPs) and kidney transplant recipients (KTxRs) are at high risk for COVID-19 [3]. Brazil has the world’s third highest number of chronic DPs and the second highest absolute number of KTxRs worldwide, which both focus attention on COVID-19 in these Brazilian cohorts [4,5]. The long-term use of immunosuppression in KTxRs is a matter of debate, with some arguing that the immunosuppression would predispose them to a greater risk of severe infection [6]. Others speculate that immunosuppressive therapy may be protective against the COVID-19–induced cytokine storm [7]. DPs are at high risk of COVID-19 infection because they require frequent travel to the dialysis facility using public transportation and because they have close contact with the staff and other patients within the dialysis unit [8].

The aim of the present study was to compare the outcomes of DPs and KTxRs with COVID-19.

*Address correspondence to Mario Abbud-Filho, MD, PhD, Departamento de Medicina/Nefrologia, Laboratório de Imunologia e Transplante Experimental - LITEX, Faculdade de Medicina de São José do Rio Preto - FAMERP, Brigadeiro Faria Lima Avenue, number 5416, 15090-000 São José do Rio Preto, SP, Brazil. Tel: (+55) 173201-5739. E-mail: mabbud@gmail.com

© 2022 Elsevier Inc. All rights reserved.
230 Park Avenue, New York, NY 10169

0041-1345/20
https://doi.org/10.1016/j.transproceed.2022.02.061
METHODS

Study Population

We conducted a prospective, observational, single-center study, and data were collected from registry files of 266 patients who tested positive for COVID-19, 154 KTxRs and 112 DPs, during the period from March 1, 2020, to June 30, 2021. Patients suspected with having COVID-19 were tested with real-time reverse transcription polymerase chain reaction (RT-PCR) or SARS-CoV-2 antigen test (Ag-Test) on 1380 kidney replacement therapy patients (500 DPs and 880 KTxRs) from a metropolitan region comprising 2 million inhabitants. The study protocol was approved by the institutional review board (4212395) and was performed in accordance with the Declaration of Helsinki as well as the Declaration of Istanbul 2008.

Statistical Analysis

The parametric data group comparisons were made using a t test or one-way analysis of variance. Group comparisons of nonparametric data were carried out using the Mann-Whitney or Kruskal-Wallis test. The data were analyzed using Statistica 9.0 software (Statsoft Inc., Tulsa, OK, USA). Data are presented as mean ± standard deviation, and P < .05 was considered statistically significant.

RESULTS

Dialysis Patients

Of 511 patients suspected to have COVID-19, 112 tested positive for COVID-19 by RT-PCR. The majority, 85%, were undergoing hemodialysis, and 15% were undergoing home peritoneal dialysis, having an average dialysis time of 43 ± 41 months.

Kidney Transplant Recipients

Out of 526 KTxRs tested, 154 had COVID-19 confirmed by RT-PCR (89%) or Ag-Test (11%). Of the KTxRs positive with COVID-19, 79% received transplants from deceased donors, with an average time of transplant of approximately 85 ± 67 months. Immunosuppression regimen was based on calcineurin inhibitors (71%) associated with mycophenolic acid (51%) or mammalian target of rapamycin inhibitors (5.3%) or azathioprine (13%). Only 1.3% were receiving a steroid-free regimen.

DP vs KTxR groups

KTxRs were younger, presented higher body mass index, and had fewer coexisting disorders (cardiovascular disease, hypertension, diabetes mellitus, lung disease; Table 1) than DPs.

Classical symptoms, such as fever, cough, and dyspnea, were more frequent in the DPs than in KTxRs. Changes in biochemistry and hematological and inflammatory markers were higher in the KTxRs than the DPs. Interestingly, lower hemoglobin and higher alkaline phosphatases were seen more frequently in the DPs (Table 1).

KTxRs required more hospitalization and intensive care unit admissions, and no significant differences were found between the 2 groups concerning the fatality rate. The mean age at death was higher in the DP group (Table 1).

The incidence rate of COVID-19 in the DP group was 2240/10,000 patients with a mortality rate of 480/10,000 patients and a fatality rate 24%. In the KTxR group, the incidence rate was 1750/10,000 patients with a mortality rate of 420.4/10,000 patients and a fatality rate of 24%.

Discussion

The incidence of COVID-19 infection in the general Brazilian population is 1002.8/10,000 inhabitants, much lower than in the DP group (2240/10,000 inhabitants) and the KTxR group (1750/10,000 inhabitants). The highest incidence found in the DP may be because of the higher exposure during the shared transport and frequently close contact with staff and other patients, and in KTxR possibly because of the consultation and hospitalization contamination.

The general Brazilian population mortality was of 28/10,000 inhabitants and a fatality rate of 2.8% [5], lower than the DPs (mortality of 480/10,000 inhabitants and a fatality rate of 24%) and the KTxRs (mortality rate of 420.4/10,000 inhabitants and a fatality rate of 24%), showing the higher risk of death for COVID-19 infection in these populations.

Even with the higher incidence and mortality rates observed in the DPs and the KTxRs, their fatality rate did not differ. The KTxR and DP mortality rates (24%) in our study were similar in the DPs (24.9%) of the Spanish study, but higher in the KTxRs (18.6%) found in the same Spanish study [10]. However, these findings were higher in both DPs and KTxRs than in the multicenter European group study (21.2% and 20.2%, respectively) [11]. The high fatality rate found in DPs can be explained by the fact that this population is older and has more coexisting disorders (Table 1), in agreement with other studies [3,10,11]. In spite of the KTxRs being younger and with fewer comorbidities than the dialysis group, these results are similar to the multicenter European group study [11].

Comparing other outcomes, the KTxRs presented more hospitalization and more intensive care unit need than the DPs. In addition, a European study comparing the mortality between the KTxRs and DPs shows that the mortality risk in KTxRs with COVID-19 was 28% higher than in the selected matched group of DPs [11].

A recent study from Madrid reported some inflammatory markers as predictors of severe COVID-19 in the general population [12]. A COVID-19 analysis in DPs in the same hospital in Brazil showed that those markers were significantly higher in the severe form of COVID-19, whereas hemoglobin and lymphocyte counts were significantly lower [9]. Our study found that the neutrophil lymphocyte ratio, C-reactive protein, lactate dehydrogenase, and liver enzymes were more frequently higher in the KTxRs than in the DPs, which could mean more severe disease.

CONCLUSIONS

Our results suggest that the clinical spectrum of COVID-19 between KTxRs and DPs has much higher fatality and mortality rates compared with the general Brazilian population. Additionally, KTxRs, in spite of having fewer comorbidities and younger age, had similar mortality and fatality rates, as well as incidence of COVID-19, as the DP group.
Table 1. Demographic Characteristics and Outcomes of Patients With COVID-19 in Dialysis or Kidney Transplant

| Characteristics and Outcomes | DP Group (n = 112) | KTxR Group (n = 154) | P Value |
|------------------------------|-------------------|---------------------|---------|
| Age (y), mean (SD)           | 61 ± 14.6         | 49 ± 12.4           | <.0001  |
| Sex, male [n (%)]            | 63 (56)           | 93 (60)             | .52     |
| Race (W/NW)                  | 88/24             | 109/45              | –       |
| BMI (kg/m²), mean (SD)       | 24.3 ± 4.6        | 27.7 ± 4.8          | <.0001  |
| Coexisting disorder [n (%)]  |                   |                     |         |
| Cardiovascular disease       | 46 (41)           | 23 (15)             | <.0001  |
| Hypertension                 | 105 (94)          | 130 (88.4)          | .02     |
| Diabetes mellitus            | 55 (49)           | 51 (33)             | .01     |
| Lung disease                 | 25 (22.3)         | 8 (5.2)             | <.0001  |
| Symptoms [n (%)]             |                   |                     |         |
| Fever                        | 68 (61)           | 52 (34)             | <.0001  |
| Cough                        | 68 (61)           | 58 (37.7)           | .0003   |
| Dyspnea                      | 55 (49)           | 13 (8.4)            | <.0001  |
| Laboratory findings, median (IQR) |
| Hemoglobin, g/dL             | 10.4 ± 2          | 12.3 ± 2            | <.0001  |
| Platelets, per mm³           | 189 ± 124         | 182 ± 76            | .09     |
| Leukocytes, per mm³          | 5365 ± 2447       | 7048 ± 4923         | .007    |
| Lymphocytes, per mm³         | 966 ± 556         | 832 ± 520           | .008    |
| Neutrophils, per mm³         | 3809 ± 2200       | 5571 ± 4414         | <.0001  |
| Neutrophil lymphocyte ratio  | 6.15 ± 10         | 9.3 ± 9.6           | .004    |
| C-reactive protein, mg/dL    | 8.05 ± 9.5        | 11 ± 14.4           | .04     |
| Aspartate aminotransferase, U/L| 28.4 ± 29        | 40 ± 30             | <.0001  |
| Alanine aminotransferase, U/L| 20.4 ± 27         | 30.4 ± 24           | <.0001  |
| Total serum bilirubin, mg/dL | 0.30 ± 0.19       | 0.38 ± 0.29         | .005    |
| Gamma-glutamyl transpeptidase, U/L| 107.8 ± 234    | 134.6 ± 171         | .01     |
| Alkaline phosphatase, IU/L   | 126 ± 104         | 94 ± 46             | .0006   |
| D-dimer, µg/mL               | 1.86 ± 1.5        | 1.98 ± 2.2          | .22     |
| Lactate dehydrogenase, U/L   | 293.6 ± 105       | 382.2 ± 190         | .0001   |
| Hospitalization [%]          | 70%               | 49.4%               | .002    |
| ICU [%]                      | 39%               | 25%                 | .01     |
| Death [n (%)]                | 27 (24)           | 37 (24)             | .55     |
| 30-day fatality rate [n (%)] | 4 (3.6)           | 2 (1.3)             | .24     |
| Age at death, mean (SD)      | 63 ± 15           | 54 ± 10.6           | .007    |
| Incidence rate/10,000        | 2.240             | 1.750               | –       |
| Mortality rate/10,000        | 480               | 420.4               | –       |
| Fatality rate, %             | 24                | 24                  | .55     |

The incidence, mortality and case fatality rates were calculated as follows: Incidence = number of cases from March 1, 2020 until the end of the current report (June 31, 2020); number of exposed people per 10,000. Mortality = number of deaths due to COVID-19/number of exposed people per 10,000. Fatality = (number of confirmed COVID-19 deaths owing to COVID-19/number of confirmed COVID-19 cases) × 100.

DP, dialysis patients; KTxR, kidney transplant recipient; SD, standard deviation; M, male; W, white; NW, nonwhite; BMI, body mass index; ICU, intensive care unit; IQR, interquartile range.

REFERENCES

[1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.

[2] Brazilian Ministry of Health. Coronavírus Brasil. Painel de dados de casos de doença pelo coronavírus 2019 (COVID-19) no Brasil pelo Ministério da Saúde, September 16, 2021. https://covid.saude.gov.br/.[accessed 28.10.21].

[3] Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant 2020;35:1973–83.

[4] Censo de Diálise da Sociedade Brasileira de Nefrologia 2020 [Dialysis Census of the Brazilian Society of Nephrology], <https://www.censo-sbn.org.br/censosAnteriores>; 2020 [accessed 31.03.21].

[5] Registro Brasileiro de Transplantes (RBT) 2020. Dimensionamento dos Transplantes no Brasil e em cada Estado (2013-2020). Veículo Oficial da Associação Brasileira de Transplantes de Órgãos. Ano XXVI No 4 [Brazilian Registry of Transplants 2020, Sizing of Transplants in Brazil and in Each State (2013-2020). Official Vehicle of the Brazilian Association of Organ Transplants. Year XXVI Number 4], <http://abto.org.br>; [accessed 31.03.21].

[6] Coates PT, Wong G, Drueke T, Rovin B, Ronco P. Early experience with COVID-19 in kidney transplantation. Kidney Int 2020;97:1074–5.

[7] Tay MZ, Poh CM, Ribeiro L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020;20:363–74.

[8] Rombola G, Heidemengerh M, Pedrini L, Farina M, Aucella F, Messa P, et al. Practical indications for the prevention and management of SARS-CoV-2 in ambulatory dialysis patients: lessons from the first phase of the epidemics in Lombardy. J Nephrol 2020;33:193–6.

[9] Gorayeb-Polacchini FS, Caldas HC, Bottazzo AC, Abbad-Filho M. SARS-CoV-2 assessment in an outpatient dialysis facility of a single center in Brazil. Braz J Infect Dis 2021;25:101595.
[10] Sánchez-Álvarez JE, Pérez Fontán M, Jiménez Martín C, Blasco Pelícano M, Cabezas Reina CJ, Sevillano Prieto AM, et al. SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN). Nefrologia (Engl Ed) 2020;40:272–8.

[11] Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int 2020;98:1540–8.

[12] Soriano V, Ganado-Pinilla P, Sanchez-Santos M, Gómez-Gallego F, Barreiro P, de Mendoza C, et al. Main differences between the first and second waves of COVID-19 in Madrid, Spain. Int J Infect Dis 2021;105:374–6.